NR1I3 and Hepatic steatosis: Activation of CAR has been associated with both beneficial effects, such as mitigating hepatic steatosis, and adverse outcomes, such as exacerbating hepatic fibrosis and hepatocarcinogenesis, depending on the experimental context [18,19].